MetaStat (MetaStat) Dividend Payout Ratio : 0.00 (As of Feb. 2018)

View and export this data going back to 2008. Start your Free Trial

What is MetaStat Dividend Payout Ratio?

MetaStat's dividend payout ratio for the months ended in Feb. 2018 was 0.00.

The historical rank and industry rank for MetaStat's Dividend Payout Ratio or its related term are showing as below:

MTST's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-25), the Dividend Yield % of MetaStat is 0.00%.

MetaStat's Dividends per Share for the months ended in Feb. 2018 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

MetaStat Dividend Payout Ratio Historical Data

The historical data trend for MetaStat's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Dividend Payout Ratio Chart

MetaStat Annual Data

Trend

Feb09

Feb10

Feb11

Feb12

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Dividend Payout Ratio

Get a 7-Day Free Trial

MetaStat Quarterly Data
	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Aug16	Nov16	Feb17	May17	Aug17	Nov17	Feb18
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MetaStat's Dividend Payout Ratio

For the Biotechnology subindustry, MetaStat's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where MetaStat's Dividend Payout Ratio falls into.

MetaStat Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

MetaStat's Dividend Payout Ratio for the fiscal year that ended in Feb. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Feb. 2018 )	/	EPS without NRI (A: Feb. 2018 )
	=	0	/	-0.7
	=	N/A

MetaStat's Dividend Payout Ratio for the quarter that ended in Feb. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2018 )	/	EPS without NRI (Q: Feb. 2018 )
	=	0	/	-0.159
	=	N/A

MetaStat (OTCPK:MTST) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

MetaStat Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of MetaStat's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

MetaStat (MetaStat) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210

Website

http://www.metastat.com

MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.

Executives

Daniel H Schneiderman	officer: VP OF FINANCE AND SECRETARY	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings	director	11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll	director	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor	director	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel	director	T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau	director	2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein	director	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins	10 percent owner	730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz	director	10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines